| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the University of Colorado Health Sciences Center (Dr. Badesch), Denver, CO; The Children’s Hospital (Dr. Abman), Denver, CO; Babies Hospital (Dr. Barst), Columbia-Presbyterian Medical Center, Pediatric-Cardiology Center, New York, NY; Duke University Medical Center (Drs. Ahearn and McCrory), Durham, NC; Hôpital Antoine Béclère (Dr. Simonneau), Clamart, France; and University of Michigan (Dr. McLaughlin), Ann Arbor, MI.
Correspondence to: David B. Badesch, MD, FCCP, University of Colorado Health Sciences Center, Box C-272, 4200 E Ninth Ave, Denver, CO 80262; e-mail: David.Badesch{at}UCHSC.edu
Pulmonary arterial hypertension (PAH) is often difficult to diagnose and challenging to treat. Untreated, it is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. The past decade has seen remarkable improvements in therapy, driven largely by the conduct of randomized controlled trials. Still, the selection of most appropriate therapy is complex, and requires familiarity with the disease process, evidence from treatment trials, complicated drug delivery systems, dosing regimens, side effects, and complications. This chapter will provide evidence-based treatment recommendations for physicians involved in the care of these complex patients. Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center.
Key Words: anticoagulation • arginine • beraprost • bosentan • calcium-channel blockers • endothelin • endothelin receptor antagonist • epoprostenol • idiopathic pulmonary arterial hypertension • iloprost • medical therapy • oxygen • primary pulmonary hypertension • prostacyclin • pulmonary arterial hypertension • pulmonary hypertension • secondary pulmonary hypertension • sildenafil • therapy • treatment • treprostinil • vasoreactivity • warfarin
This article has been cited by other articles:
|
|
 |
|
  D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials Chest, September 1, 2007; 132(3): 764 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Johnson, S. Mehta, and J. T. Granton Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur. Respir. J., November 1, 2006; 28(5): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Voelkel, R. A. Quaife, L. A. Leinwand, R. J. Barst, M. D. McGoon, D. R. Meldrum, J. Dupuis, C. S. Long, L. J. Rubin, F. W. Smart, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation, October 24, 2006; 114(17): 1883 - 1891. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Newman and I. M. Robbins Exercise Training in Pulmonary Hypertension: Implications for the Evaluation of Drug Trials Circulation, October 3, 2006; 114(14): 1448 - 1449. [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Borden, S. Rich, and M. Gomberg SUCCESS WITH CALCIUM-CHANNEL BLOCKERS IN A PATIENT WHO FAILED BOSENTAN THERAPY FOR IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION Chest Meeting Abstracts, October 1, 2006; 130(4): 306S - 307S. [Abstract] [PDF]
|
|
|
|
 |
|
 B. S. Zuckerbraun, B. Y. Chin, B. Wegiel, T. R. Billiar, E. Czsimadia, J. Rao, L. Shimoda, E. Ifedigbo, S. Kanno, and L. E. Otterbein Carbon monoxide reverses established pulmonary hypertension J. Exp. Med., September 4, 2006; 203(9): 2109 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest, September 1, 2006; 130(3): 841 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Reichenberger, R. Voswinckel, E. Steveling, B. Enke, A. Kreckel, H. Olschewski, F. Grimminger, W. Seeger, and H. A. Ghofrani Sildenafil treatment for portopulmonary hypertension Eur. Respir. J., September 1, 2006; 28(3): 563 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A.B. Smith, J. A. Canter, K. G. Christian, D. C. Drinkwater, F. G. Scholl, B. W. Christman, G. D. Rice, F. E. Barr, and M. L. Summar Nitric oxide precursors and congenital heart surgery: A randomized controlled trial of oral citrulline J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Elliott, E. W. Glissmeyer, G. T. Havlena, J. Carlquist, J. T. McKinney, S. Rich, M. D. McGoon, M. B. Scholand, M. Kim, R. L. Jensen, et al. Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension Circulation, May 30, 2006; 113(21): 2509 - 2515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert, O. Sitbon, A. Chaouat, M. Bertocchi, G. Habib, V. Gressin, A. Yaici, E. Weitzenblum, J.-F. Cordier, F. Chabot, et al. Pulmonary Arterial Hypertension in France: Results from a National Registry Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 1023 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin Pulmonary arterial hypertension. Proceedings of the ATS, January 1, 2006; 3(1): 111 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Provencher, X. Jais, A. Yaici, O. Sitbon, M. Humbert, and G. Simonneau Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture Chest, December 1, 2005; 128(6_suppl): 622S - 628S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, and J. Niedermeyer Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur. Respir. J., November 1, 2005; 26(5): 858 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E Baker and R. H. Hockman Inhaled Iloprost in Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ford Pulmonary artery hypertension: new drug treatment in children Arch. Dis. Child. Ed. Pract., June 1, 2005; 90(1): ep15 - ep20. [Full Text] [PDF]
|
|
|
|
|
|
A. J Lee, T. B Chiao, and M. P Tsang Sildenafil for Pulmonary Hypertension Ann. Pharmacother., May 1, 2005; 39(5): 869 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A Reisbig, P. A Coffman, A. A Floreani, C. J Bultsma, and K. M Olsen Staggered Transition to Epoprostenol from Treprostinil in Pulmonary Arterial Hypertension Ann. Pharmacother., April 1, 2005; 39(4): 739 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Humbert Improving survival in pulmonary arterial hypertension Eur. Respir. J., February 1, 2005; 25(2): 218 - 220. [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin, O. Sitbon, D. B. Badesch, R. J. Barst, C. Black, N. Galie, M. Rainisio, G. Simonneau, and L. J. Rubin Survival with first-line bosentan in patients with primary pulmonary hypertension Eur. Respir. J., February 1, 2005; 25(2): 244 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Huisman, S. A. Vreugdenhil, H. C. van Paassen, M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., January 20, 2005; 352(3): 308 - 309. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
